首页> 外文期刊>Stem Cells and Cloning: Advances and Applications >Age-old wisdom concerning cell-based therapies with added knowledge in the stem cell era: our perspectives
【24h】

Age-old wisdom concerning cell-based therapies with added knowledge in the stem cell era: our perspectives

机译:关于干细胞时代基于细胞的疗法和更多知识的古老智慧:我们的观点

获取原文
           

摘要

Among the various strategies providing a cure for illness, cell-based therapies have caught the attention of the world with the advent of the "stem cell" era. Our inherent understanding indicates that stem cells have been in existence since the birth of multicellular organisms. However, the formal discovery of stem cells in the last century, followed by their intricate and extensive analysis, has led to clinical and translational efforts with the aim of using them in the treatment of conditions which don't have a definitive therapeutic strategy, has fueled our interest and expectations. Technological advances in our ability to study their cellular components in depth, along with surface markers and other finer constituents, that were unknown until last century, have improved our understanding, leading to several novel applications. This has created a need to establish guidelines, and in that process, there are expressed understandings and views which describe cell therapy along lines similar to that of biologic products, drugs, and devices. However, the age-old wisdom of using cells as tools for curing illness should not be misled by recent knowledge, to make cell therapy using highly complex stem cells equal to factory-synthesized and reproducible chemical compounds, drugs, or devices. This article analyses the differences between these two entities from various perspectives.
机译:在提供治疗疾病的各种策略中,基于细胞的疗法随着“干细胞”时代的到来引起了世界的关注。我们固有的理解表明,自多细胞生物诞生以来,干细胞就已经存在。然而,上个世纪正式发现干细胞,随后对其进行了复杂而广泛的分析,导致了临床和转化方面的努力,目的是将干细胞用于治疗没有明确治疗策略的疾病。激发了我们的兴趣和期望。我们深入研究其细胞成分以及表面标记和其他更精细成分的能力的技术进步(直到上个世纪才知道)改善了我们的理解,并导致了许​​多新颖的应用。这就需要建立指导方针,并且在此过程中,表达出的理解和观点描述了与生物产品,药物和设备类似的疗法。但是,使用细胞作为治疗疾病的工具的古老智慧不应被最新知识所误导,以使使用高度复杂的干细胞进行细胞疗法等于工厂合成且可复制的化合物,药物或装置。本文从不同角度分析了这两个实体之间的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号